Federal Register / Vol. 63, No. 122 /Thursday, June 25, 1998 / Notices 34651

FEDERAL MARITIME COMMISSION

Notice of Agreement(s) Filed

The Commission hereby gives notice

of the filing of the following

agreement(s) under the Shipping Act of

1984.

Interested parties can review or obtain

copies of agreements at the Washington,

DC offices of the Commission, 800

North Capitol Street, NW., Room 962.

Interested parties may submit comments

on an agreement to the Secretary,

Federal Maritime Commission,

Washington, DC 20573, within 10 days

of the date this notice appears in the

Federal Register.

Agreement No.: 224–200993–001

Title: Oakland-Yang Ming Terminal Use

Agreement

Parties:

Port of Oakland Yang Ming Marine

Transport Corporation

Synopsis: The proposed amendment

allows Yang Ming’s cargo handled at

Howard Terminal to and from Cosco

vessels to be treated as Yang Ming’s

cargo being handled at Seventh Street

Terminal to and from Yang Ming

vessels. Cosco’s cargo handled at

Seventh Street Terminal to and from

Yang Ming vessels will be treated as

Cosco cargo being handled at Howard

Terminal. The term of the agreement

continues to run through May 1, 2001.

Dated: June 19, 1998.

By Order of the Federal Maritime

Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 98–16903 Filed 6–24–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License

Applicants

Notice is hereby given that the

following applicants have filed with the

Federal Maritime Commission

applications for licenses as ocean

freights forwarders pursuant to section

19 of the Shipping Act of 1984 (46

U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why

any of the following applicants should

not receive a license are requested to

contact the Office of Freight Forwarders,

Federal Maritime Commission,

Washington, DC 20573.

IFS Film Services, Inc., 6521 NW 87th

Avenue, Miami, FL 33178, Officer:

Mayde C. Montesano, Director.

Dated: June 22, 1998.

Joseph C. Polking,

Secretary.

[FR Doc. 98–16902 Filed 6–24–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than July 19, 1998.

A. Federal Reserve Bank of

Minneapolis (Karen L. Grandstrand,

Vice President) 90 Hennepin Avenue,

P.O. Box 291, Minneapolis, Minnesota

55480-0291:

1. Community Bank Minnesota

Employee Stock Ownership Plan,

Owatonna, Minnesota; to become a bank

holding company by acquiring an

additional 9.57 percent, for a total of

29.70 percent, of the voting shares of

Owatonna Bancshares, Inc., Owatonna,

Minnesota, and thereby indirectly

acquire Community Bank Minnesota,

Owatonna, Minnesota.

2. Norwest Corporation, Minneapolis,

Minnesota; to acquire 100 percent of the

voting shares of Star Bancshares, Inc.,

Austin, Texas, and thereby indirectly

acquire Star Bancshares of Nevada, Inc.,

Carson City, Nevada, and First State

Bank, Austin, Texas.

B. Federal Reserve Bank of Dallas

(W. Arthur Tribble, President) 2200

North Pearl Street, Dallas, Texas 75201-

2272:

1. Independent Bankshares, Inc.,

Abiliene, Texas; to acquire 100 percent

of the voting shares of Azle Bancorp,

Azle, Texas, and thereby indirectly

acquire Azle Holdings, Inc., Azle, Texas,

and Azle State Bank, Azle, Texas.

2. McLaughlin Bancshares, Inc., Ralls,

Texas; to acquire 100 percent of the

voting shares of First Petersburg

Bancshares, Inc., Petersburg, Texas, and

thereby indirectly acquire First State

Bank, Petersburg, Texas.

Board of Governors of the Federal Reserve

System, June 19, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–16836 Filed 6–24–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[30DAY–16–98]

Agency Forms Undergoing Paperwork

Reduction Act Review

The Centers for Disease Control and

Prevention (CDC) publishes a list of

information collection requests under

review by the Office of Management and

Budget (OMB) in compliance with the

Paperwork Reduction Act (44 U.S.C.

Chapter 35). To request a copy of these

requests, call the CDC Reports Clearance

Officer at (404) 639–7090. Send written

comments to CDC, Desk Officer; Human

Resources and Housing Branch, New

Executive Office Building, Room 10235;

Washington, DC 20503. Written

comments should be received within 30

days of this notice.

Proposed Projects

1. Breast Cancer Incidence in an

Occupational Cohort Exposed to

Ethylene Oxide and in an Occupational

Cohort Exposed to Polychlorinated

Biphenyls (0920–0366)—National

Institute for Occupational Safety and

Health (NIOSH)—Extension—Breast

cancer is the most common incident

cancer among U.S. women, and the

second leading cause of cancer mortality

in U.S. women. Increasing numbers of

women are employed outside the home,

yet few studies of breast cancer etiology

have addressed occupational and

environmental chemical exposures, and
34652 Federal Register / Vol. 63, No. 122 /Thursday, June 25, 1998 / Notices

many cancer studies of industrial

cohorts have excluded women. This

study will provide information

concerning: (1) the incidence of breast

cancer in a cohort of women exposed to

ethylene oxide (ETO), and (2) the

incidence of breast cancer in a cohort of

women exposed to polychlorinated

biphenyls (PCBs). Both compounds are

suspected breast carcinogens. These two

cohorts have been previously assembled

by NIOSH, and each represents the

largest and best defined female study

cohort in the U.S. for the respective

exposure.

All women in the existing NIOSH

ethylene oxide cohort (n=9,929) and

PCB cohort (13,736) will be enrolled in

the study. For both cohorts, data from

personnel records has been coded into

a computer file containing demographic,

and work history information. This

information will be used to estimate

workplace exposures. Vital status has

been determined through automated

data sources. Questionnaires are

currently being mailed to each living

cohort member to obtain information on

breast cancer incidence and risk factors

for breast cancer. For deceased cohort

members, next-of-kin will be asked to

provide this information. Other record

sources such as death certificates and

population-based cancer incidence

registries will also be used to identify

cancer cases. The diagnosis will be

confirmed by medical records. Each

questionnaire will take approximately

30 minutes to complete. Total annual

burden hours are 12,500.

Respondents Number of

respondents

Number of

responses/

respondent

Avg. burden/response

(in hours)

Total burden

(in hours)

Workers ............................................................................................................................ 23,000 1 .50 11,500

Medical providers ............................................................................................................. 2,000 1 .50 1,000

2. Tests and Requirements for

Certification and Approval of

Respiratory Protective Devices—42 CFR

84—Regulation—(0920–0109)—

Extension—The regulatory authority for

the National Institute for Occupational

Safety and Health (NIOSH) certification

program for respiratory protective

devices is found in the Mine Safety and

Health Amendments Act of 1977 (30

U.S.C. 577a, 651 et seq., and 657(g)) and

the Occupational Safety and Health Act

of 1970 (30 U.S.C. 3, 5, 7, 811, 842(h),

844). These regulations have, as their

basis, the performance tests and criteria

for approval of respirators used by

millions of American construction

workers, miners, painters, asbestos

removal workers, fabric mill workers,

and fire fighters. In addition to

benefitting industrial workers, the

improved testing requirements also

benefit health care workers

implementing the current CDC

Guidelines for Preventing the

Transmission of Tuberculosis.

Regulations of the Environmental

Protection Agency (EPA) and the

Nuclear Regulatory Commission (NRC)

also require the use of NIOSH-approved

respirators.

NIOSH, in accordance with

implementing regulations 42 CFR 84: (1)

Issues certificates of approval for

respirators which have met improved

construction, performance, and

protection requirements; (2) establishes

procedures and requirements to be met

in filing applications for approval; (3)

specifies minimum requirements and

methods to be employed by NIOSH and

by applicants in conducting inspections,

examinations, and tests to determine

effectiveness of respirators; (4)

establishes a schedule of fees to be

charged applicants for testing and

certification, and (5) establishes

approval labeling requirements. Total

annual burden hours are 177,968.

Respondents (section/data type) Number of

respondents

Number of

responses/

respondent

Average

burden/response

(in hours)

Total burden

(in hours)

84.11/Applications ............................................................................................................ 56 14.0 63.56 49,831

84.33/Labeling .................................................................................................................. 56 14.0 1.54 1,207

84.35/Modifications ........................................................................................................... 56 14.0 79.45 62,289

84.41/Reporting ................................................................................................................ 56 14.0 22.70 17,797

84.43/Record keeping ...................................................................................................... 56 14.0 56.75 44,492

84.257/Labeling ................................................................................................................ 56 14.0 1.50 1,176

84.1103/Labeling .............................................................................................................. 56 14.0 1.50 1,176

Dated: June 18, 1998.

Charles W. Gollmar,

Acting Associate Director for Policy Planning

and Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–16752 Filed 6–24–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 92N–0429]

Constantine I. Kostas; Denial of

Hearing; Final Debarment Order

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) denies a request

for a hearing and issues a final order

under the Federal Food, Drug, and

Cosmetic Act (the act) permanently

debarring Constantine I. Kostas, Nine

Cedar Mill Rd., Lynnfield, MA 01940,

from providing services in any capacity

to a person that has an approved or

pending drug product application. FDA

bases this order on its finding that Dr.

Kostas was convicted of felonies under

Federal law for conduct relating to the

development or approval, including the

process for development or approval, of

a drug product, and conduct relating to